GCM
CTMX icon

Gladius Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Gladius Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,172
Closed -$25K – 407
2022
Q2 		$25K Buy
+13,172
New +$25.2K ﹤0.01% 306

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Gladius Capital Management's CTMX Position: Q3 2022 in Review

Gladius Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 13,172 shares — an estimated $25K sold.

Gladius Capital Management first reported a position in CTMX in Q2 2022 and held it in 1 quarter. The position peaked at $25K in Q2 2022. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • Gladius Capital Management reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 13,172 CytomX Therapeutics shares in Q3 2022, an estimated $25K.
  • Gladius Capital Management first reported a position in CytomX Therapeutics in Q2 2022 and held it in 1 quarter.
  • Gladius Capital Management's CytomX Therapeutics position peaked at $25K in Q2 2022.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.